US20150374695A1 - 6-piperazinyl-3,4-dihydroquinazolin-2(1h)-ones - Google Patents
6-piperazinyl-3,4-dihydroquinazolin-2(1h)-ones Download PDFInfo
- Publication number
- US20150374695A1 US20150374695A1 US14/848,058 US201514848058A US2015374695A1 US 20150374695 A1 US20150374695 A1 US 20150374695A1 US 201514848058 A US201514848058 A US 201514848058A US 2015374695 A1 US2015374695 A1 US 2015374695A1
- Authority
- US
- United States
- Prior art keywords
- aromatic
- compound
- dihydroquinazolin
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VMOADUVHIAFSGI-UHFFFAOYSA-N 6-piperazin-1-yl-3,4-dihydro-1H-quinazolin-2-one Chemical class N1(CCNCC1)C=1C=C2CNC(NC2=CC1)=O VMOADUVHIAFSGI-UHFFFAOYSA-N 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims description 12
- -1 dihydroquinazolinone compound Chemical class 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 244000215068 Acacia senegal Species 0.000 claims description 3
- 235000006491 Acacia senegal Nutrition 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 45
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 238000006268 reductive amination reaction Methods 0.000 abstract description 8
- 239000000018 receptor agonist Substances 0.000 abstract description 7
- 229940044601 receptor agonist Drugs 0.000 abstract description 7
- 239000002464 receptor antagonist Substances 0.000 abstract description 7
- 229940044551 receptor antagonist Drugs 0.000 abstract description 7
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 abstract description 6
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 abstract description 5
- IUVSEUFHPNITEQ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CN2CCN(CC2)C=2C=3OCCOC=3C=CC=2)=C1 IUVSEUFHPNITEQ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 229950006393 adoprazine Drugs 0.000 abstract description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract description 2
- 229940127236 atypical antipsychotics Drugs 0.000 abstract description 2
- GCPNYWLULZCQOW-UHFFFAOYSA-N 1-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound O=C1NCC2=CC=CC=C2N1N1CCNCC1 GCPNYWLULZCQOW-UHFFFAOYSA-N 0.000 abstract 1
- 150000001499 aryl bromides Chemical class 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- 125000003118 aryl group Chemical group 0.000 description 35
- 239000000203 mixture Substances 0.000 description 27
- 239000000543 intermediate Substances 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 201000000980 schizophrenia Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000004547 Hallucinations Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- KGYGOVDSRDQRBQ-UHFFFAOYSA-N 6-[4-[[5-(cyclopenten-1-yl)pyridin-3-yl]methyl]piperazin-1-yl]-3,4-dihydro-1H-quinazolin-2-one Chemical compound C1(=CCCC1)C=1C=C(C=NC1)CN1CCN(CC1)C=1C=C2CNC(NC2=CC1)=O KGYGOVDSRDQRBQ-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000164 antipsychotic agent Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- IYLBKDOMXYINRT-UHFFFAOYSA-N 6-[4-[(4-phenylphenyl)methyl]piperazin-1-yl]-3,4-dihydro-1H-quinazolin-2-one Chemical compound C1(=CC=C(C=C1)CN1CCN(CC1)C=1C=C2CNC(NC2=CC1)=O)C1=CC=CC=C1 IYLBKDOMXYINRT-UHFFFAOYSA-N 0.000 description 3
- QGDSUQIKWVNPMB-UHFFFAOYSA-N 6-[4-[(5-phenylpyridin-3-yl)methyl]piperazin-1-yl]-3,4-dihydro-1H-quinazolin-2-one Chemical compound C1(=CC=CC=C1)C=1C=C(C=NC1)CN1CCN(CC1)C=1C=C2CNC(NC2=CC1)=O QGDSUQIKWVNPMB-UHFFFAOYSA-N 0.000 description 3
- LJCMSUJIPDXMBI-UHFFFAOYSA-N 6-[4-[[3-(cyclopenten-1-yl)phenyl]methyl]piperazin-1-yl]-3,4-dihydro-1H-quinazolin-2-one Chemical compound C1(=CCCC1)C=1C=C(CN2CCN(CC2)C=2C=C3CNC(NC3=CC2)=O)C=CC1 LJCMSUJIPDXMBI-UHFFFAOYSA-N 0.000 description 3
- VYBMEOMFUCXKQN-UHFFFAOYSA-N 6-[4-[[4-(4-fluorophenyl)phenyl]methyl]piperazin-1-yl]-3,4-dihydro-1H-quinazolin-2-one Chemical compound FC1=CC=C(C=C1)C1=CC=C(C=C1)CN1CCN(CC1)C=1C=C2CNC(NC2=CC1)=O VYBMEOMFUCXKQN-UHFFFAOYSA-N 0.000 description 3
- WMBTVBXPRTWXFU-UHFFFAOYSA-N 6-[4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazin-1-yl]-3,4-dihydro-1H-quinazolin-2-one Chemical compound FC1=CC=C(C=C1)C=1C=C(C=NC1)CN1CCN(CC1)C=1C=C2CNC(NC2=CC1)=O WMBTVBXPRTWXFU-UHFFFAOYSA-N 0.000 description 3
- LPMQSNAFKKEZAK-UHFFFAOYSA-N 6-bromo-3,4-dihydro-1h-quinazolin-2-one Chemical compound N1C(=O)NCC2=CC(Br)=CC=C21 LPMQSNAFKKEZAK-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010012239 Delusion Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000027776 Extrapyramidal disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 231100000868 delusion Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- VMIJCSHJVMGXFK-UHFFFAOYSA-N tert-butyl 4-(2-oxo-3,4-dihydro-1H-quinazolin-6-yl)piperazine-1-carboxylate Chemical compound O=C1NC2=CC=C(C=C2CN1)N1CCN(CC1)C(=O)OC(C)(C)C VMIJCSHJVMGXFK-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- MFTURLVFLSJTPF-UHFFFAOYSA-N (5-bromo-2-nitrophenyl)methanamine Chemical compound NCC1=CC(Br)=CC=C1[N+]([O-])=O MFTURLVFLSJTPF-UHFFFAOYSA-N 0.000 description 2
- 0 *NCC1=C(N)C=CC(N2CCN(C(=O)OC(C)(C)C)CC2)=C1.CC(C)(C)OC(=O)N1CCN(C2=CC3=C(C=C2)NC(=O)NC3)CC1.[H]N1CCN(C2=CC3=C(C=C2)NC(=O)NC3)CC1 Chemical compound *NCC1=C(N)C=CC(N2CCN(C(=O)OC(C)(C)C)CC2)=C1.CC(C)(C)OC(=O)N1CCN(C2=CC3=C(C=C2)NC(=O)NC3)CC1.[H]N1CCN(C2=CC3=C(C=C2)NC(=O)NC3)CC1 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 206010019070 Hallucination, auditory Diseases 0.000 description 2
- FZEIPJFRCKFBKG-UHFFFAOYSA-N N-[(5-bromo-2-nitrophenyl)methyl]acetamide Chemical compound BrC=1C=CC(=C(CNC(C)=O)C1)[N+](=O)[O-] FZEIPJFRCKFBKG-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ZGDMAFFIYITEDP-UHFFFAOYSA-N tert-butyl 4-[3-(acetamidomethyl)-4-aminophenyl]piperazine-1-carboxylate Chemical compound C(C)(=O)NCC=1C=C(C=CC1N)N1CCN(CC1)C(=O)OC(C)(C)C ZGDMAFFIYITEDP-UHFFFAOYSA-N 0.000 description 2
- STNZFNNWXKAQSE-UHFFFAOYSA-N tert-butyl 4-[3-(acetamidomethyl)-4-nitrophenyl]piperazine-1-carboxylate Chemical compound C(C)(=O)NCC=1C=C(C=CC1[N+](=O)[O-])N1CCN(CC1)C(=O)OC(C)(C)C STNZFNNWXKAQSE-UHFFFAOYSA-N 0.000 description 2
- FGURXSANGHMRSY-UHFFFAOYSA-N tert-butyl 4-[4-amino-3-(aminomethyl)phenyl]piperazine-1-carboxylate Chemical compound NC1=C(C=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C)CN FGURXSANGHMRSY-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ISDBWOPVZKNQDW-UHFFFAOYSA-N 4-phenylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC=CC=C1 ISDBWOPVZKNQDW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 description 1
- 206010005885 Blunted affect Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- AOSBZCURIHTMHG-UHFFFAOYSA-N C.C.CC(=O)NCC1=C([N+](=O)[O-])C=CC(Br)=C1.CC(=O)NCC1=C([N+](=O)[O-])C=CC(N2CCN(C(=O)OC(C)(C)C)CC2)=C1.C[RaH].N.NCC1=C([N+](=O)[O-])C=CC(Br)=C1.O=CC1=C([N+](=O)[O-])C=CC(Br)=C1.O=CC1=CC=CC(Br)=C1 Chemical compound C.C.CC(=O)NCC1=C([N+](=O)[O-])C=CC(Br)=C1.CC(=O)NCC1=C([N+](=O)[O-])C=CC(N2CCN(C(=O)OC(C)(C)C)CC2)=C1.C[RaH].N.NCC1=C([N+](=O)[O-])C=CC(Br)=C1.O=CC1=C([N+](=O)[O-])C=CC(Br)=C1.O=CC1=CC=CC(Br)=C1 AOSBZCURIHTMHG-UHFFFAOYSA-N 0.000 description 1
- RRNFOVOGSRTROJ-UHFFFAOYSA-N CC(C)(C)CC1=CC=C(C2=CC=C(F)C=C2)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)CC1=CC=CC(C2=CCCC2)=C1.CC(C)(C)CC1=CN=CC(C2=CC=C(F)C=C2)=C1.CC(C)(C)CC1=CN=CC(C2=CC=CC=C2)=C1.CC(C)(C)CC1=CN=CC(C2=CCCC2)=C1 Chemical compound CC(C)(C)CC1=CC=C(C2=CC=C(F)C=C2)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)CC1=CC=CC(C2=CCCC2)=C1.CC(C)(C)CC1=CN=CC(C2=CC=C(F)C=C2)=C1.CC(C)(C)CC1=CN=CC(C2=CC=CC=C2)=C1.CC(C)(C)CC1=CN=CC(C2=CCCC2)=C1 RRNFOVOGSRTROJ-UHFFFAOYSA-N 0.000 description 1
- SZTFINGXYDARLX-UHFFFAOYSA-N CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1 SZTFINGXYDARLX-UHFFFAOYSA-N 0.000 description 1
- NGZQGWVRBUUTRE-UHFFFAOYSA-N CC(C)(C)CC1=CC=CC(C2=CCCC2)=C1 Chemical compound CC(C)(C)CC1=CC=CC(C2=CCCC2)=C1 NGZQGWVRBUUTRE-UHFFFAOYSA-N 0.000 description 1
- SDDBNBAXPQWWOX-UHFFFAOYSA-N CC(C)(C)CC1=CN=CC(C2=CC=CC=C2)=C1 Chemical compound CC(C)(C)CC1=CN=CC(C2=CC=CC=C2)=C1 SDDBNBAXPQWWOX-UHFFFAOYSA-N 0.000 description 1
- HFXACBLNJUKHIJ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(C2=CC3=C(C=C2)NC(=O)NC3)CC1.N#CC1=C(N)C=CC(Br)=C1.NCC1=C(N)C=CC(Br)=C1.O=C1NCC2=C(C=CC(Br)=C2)N1 Chemical compound CC(C)(C)OC(=O)N1CCN(C2=CC3=C(C=C2)NC(=O)NC3)CC1.N#CC1=C(N)C=CC(Br)=C1.NCC1=C(N)C=CC(Br)=C1.O=C1NCC2=C(C=CC(Br)=C2)N1 HFXACBLNJUKHIJ-UHFFFAOYSA-N 0.000 description 1
- GLHBSJDVRODHIV-UHFFFAOYSA-N CC1=CC=C(C2=CC(CC(C)(C)C)=CN=C2)C=C1 Chemical compound CC1=CC=C(C2=CC(CC(C)(C)C)=CN=C2)C=C1 GLHBSJDVRODHIV-UHFFFAOYSA-N 0.000 description 1
- KTYANILIEIDPDB-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(CC(C)(C)C)C=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(CC(C)(C)C)C=C2)C=C1 KTYANILIEIDPDB-UHFFFAOYSA-N 0.000 description 1
- 208000011597 CGF1 Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010014557 Emotional poverty Diseases 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019075 Hallucination, visual Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- UYQNUCUKUZNTEC-UHFFFAOYSA-N O=C1NCC2=C(C=CC(N3CCN(CC4=CC=C(C5=CC=CC=C5)C=C4)CC3)=C2)N1.O=CC1=CC=C(C2=CC=CC=C2)C=C1.[H]N1CCN(C2=CC3=C(C=C2)NC(=O)NC3)CC1 Chemical compound O=C1NCC2=C(C=CC(N3CCN(CC4=CC=C(C5=CC=CC=C5)C=C4)CC3)=C2)N1.O=CC1=CC=C(C2=CC=CC=C2)C=C1.[H]N1CCN(C2=CC3=C(C=C2)NC(=O)NC3)CC1 UYQNUCUKUZNTEC-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036467 Poverty of speech Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229950009087 bifeprunox Drugs 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000010326 executive functioning Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- XYBRWUNZRUBCGY-UHFFFAOYSA-N methyl n-(5-bromopyridin-2-yl)carbamate Chemical compound COC(=O)NC1=CC=C(Br)C=N1 XYBRWUNZRUBCGY-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000004039 social cognition Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
Definitions
- the present invention relates to compounds having a basic bicyclic structure of a dihydroquinazolin compound and bearing D 2 receptor antagonist and 5-HT 1A receptor agonist properties, a method of making the compounds, and a method for treating schizophrenia by administering an effective dose of one or more of the compounds.
- Schizophrenia is a severe psychiatric illness afflicting 1% of the population worldwide.
- FIG. 1 depicts the first-generation antipsychotics or typical antipsychotics such as chlorpromazine 1 and haloperidol 2.
- Both chlorpromazine 1 and haloperidol 2 are dopamine antagonists which alleviate positive symptoms including hallucinations, agitation and delusions but fail to control the negative symptoms such as blunted affect, emotional withdrawal and cognitive deficits.
- these therapeutics develop extrapyramidal symptoms (EPS) and hyperprolactinemia, respectively (D. C. Goff, R. I. Shader. Non-neurological side-effects of antipsychotic drugs. In S. R. Hirsch, D. Weinberger, editors. Schizophrenia. 2nd ed., Blackwell Publishing, Oxford, p.
- the ‘second-generation’ or atypical antipsychotics such as clozapine 3, depicted in FIG. 1 , combine D 2 receptor antagonism with activity at other receptors, on the premise that a suitable balance of pharmacological activity should broaden the spectrum of therapeutic efficacy and reduce EPS.
- clozapine shows significantly greater efficacy, including an improved effect on negative symptoms, and causes a marked increase in dopamine output in the prefrontal cortex (H. Y.
- Clozapine is associated with its own set of serious side effects including weight gain, diabetes and an increased risk of seizures and agranulocytosis (L. H. Lindstrom, Acta. Psychiatr. Scand., 77, 524 (1988)—incorporated herein by reference in its entirety)
- One embodiment of the present invention includes a series of intermediate compounds having the basic bicyclic structure of a dihydroquinazolin compound.
- the series of intermediate compounds demonstrate D 2 receptor antagonist and 5-HT 1A receptor agonist properties.
- the series of intermediate compounds have the piperazinyl moiety attached at the 6-position of the bicyclic dihydroquinazolin ring.
- 6-(4-(biphenyl-4-ylmethyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- 6-(4-((4′-fluorobiphenyl-4-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- 6-(4-((5-phenylpyridin-3-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- 6-(4-((5-(4-fluorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- 6-(4-(3-cyclopentenylbenzyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- 6-(4-((5-cyclopentenylpyridin-3-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- a method of making the series of intermediate compounds includes using Buchwald-Hartwig coupling a halogenized dihydroquinazolin-2(1H)-one with a tert-butyl piperazine-1-carboxylate.
- FIG. 1 displays compounds that bear 5-HT 1A receptor agonist and D 2 receptor antagonist properties
- FIG. 2 displays a series of intermediate compounds.
- FIG. 2 displays compounds 6a-f).
- FIG. 2 displays the compounds.
- the compounds are used to treat schizophrenia by administering an effective amount of the compound to a patient suffering from schizophrenia.
- An effective amount of the compound includes but is not limited to using an amount of the compound in which the compound bears D 2 receptor antagonist properties and 5-HT 1A receptor agonist properties sufficient enough to treat and/or alleviate symptoms of schizophrenia.
- Symptoms of schizophrenia include but are not limited to auditory hallucinations, visual hallucinations, olfactory hallucinations, gustatory hallucinations, hearing voices, delusions (often strange or persecutory in nature), disorganized thinking and speech, social withdrawal, sloppiness of dress and hygiene, loss of motivation and judgment, an observable pattern of emotional difficulty including lack of responsiveness, impairment in social cognition, paranoia, social isolation, difficulties in working and long-term memory, attention, executive functioning, remaining motionless in playful postures, exhibiting purposeless agitation, difficulty with facial emotion perception, manifestations of psychosis, expressing little emotion, inability to experience pleasure, and lack of desire to form relationships.
- the compound in another embodiment, can be administered in an amount in the range of 1 mg-5000 mg, 5 mg-100 mg, 5 mg-20 mg, and 5-10 mg. Preferably, the compound is administered in a dose of 5-10 mg.
- the compound may be administered once a day or twice a day. Preferably the compound is administered once a day at the same time each day. The compound may be administered at any time period of the day.
- compositions containing one or more of the compounds can be delivered to a patient by systemic administration.
- Systemic administration is an in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body.
- Administration routes that can lead to systemic absorption include but are not limited to intravenous, subcutaneous, intraperitoneal, inhalation, transdermal, oral, intrapulmonary and intramuscular routes.
- compositions of the invention and formulations thereof can be administered orally, topically, parenterally, sublingually, by inhalation or spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles.
- parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intradermal, intramuscular, or intrathecal injection or infusion techniques and the like.
- compositions can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide pharmaceutically acceptable and palatable preparations.
- Tablets may contain the active ingredient or ingredients in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
- excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
- formulations for oral use can also be presented as hard gelatin capsules wherein the intermediate is mixed with an inert solid diluent including but not limited to calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the intermediate is mixed with water or an oil medium including but not limited to peanut oil, liquid paraffin or olive oil.
- an inert solid diluent including but not limited to calcium carbonate, calcium phosphate or kaolin
- water or an oil medium including but not limited to peanut oil, liquid paraffin or olive oil.
- aqueous suspensions contain the active materials in a mixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monoole
- the aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid.
- dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent for example sweetening, flavoring and coloring agents, can also be present.
- compositions of the invention can also be in the form of oil-in-water emulsions.
- the oily phase can be a vegetable oil or a mineral oil or mixtures of these.
- Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions can also contain sweetening and flavoring agents.
- syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose.
- sweetening agents for example glycerol, propylene glycol, sorbitol, glucose or sucrose.
- Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents.
- the pharmaceutically acceptable compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
- the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- Suitable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono-or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- compositions can also be administered in the form of suppositories, e.g., for rectal administration of the drugs.
- suppositories e.g., for rectal administration of the drugs.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include but are not limited to cocoa butter and polyethylene glycols.
- aldehyde 12 3 g, 13.0 mmol
- THF 25 mL
- ammonium hydroxide 28%, 5 mL
- sodium borohydride 1.47 g, 39 mmol
- the mixture was aged at room temperature for 4 h; ethyl acetate (30 mL) and brine (15 mL) were added.
Abstract
Description
- This application is a continuation application of U.S. application Ser. No. 14/184,339.
- 1. Technical Field
- The present invention relates to compounds having a basic bicyclic structure of a dihydroquinazolin compound and bearing D2 receptor antagonist and 5-HT1A receptor agonist properties, a method of making the compounds, and a method for treating schizophrenia by administering an effective dose of one or more of the compounds.
- 2. Description of the Related Art
- The “background” description provided herein is for the purpose of generally presenting the context of the disclosure. Work of the presently named inventors, to the extent it is described in this background section, as well as aspects of the description which may not otherwise qualify as prior art at the time of filing, are neither expressly or impliedly admitted as prior art against the present invention.
- Schizophrenia is a severe psychiatric illness afflicting 1% of the population worldwide.
- The diagnosis of the disease is based on diverse and variably expressed symptoms which can be grouped as positive and negative. The positive symptoms include disorganized thought, delusions and auditory hallucinations whereas the most characteristic negative symptoms are emotional flattening, poverty of speech and motivational deficits (Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision, American Psychiatric Association, Washington, D.C, p. 297-343 (2000)—incorporated herein by reference in its entirety).
FIG. 1 depicts the first-generation antipsychotics or typical antipsychotics such as chlorpromazine 1 and haloperidol 2. Both chlorpromazine 1 and haloperidol 2 are dopamine antagonists which alleviate positive symptoms including hallucinations, agitation and delusions but fail to control the negative symptoms such as blunted affect, emotional withdrawal and cognitive deficits. In addition these therapeutics develop extrapyramidal symptoms (EPS) and hyperprolactinemia, respectively (D. C. Goff, R. I. Shader. Non-neurological side-effects of antipsychotic drugs. In S. R. Hirsch, D. Weinberger, editors. Schizophrenia. 2nd ed., Blackwell Publishing, Oxford, p. 573-88 (2002)—incorporated herein by reference in its entirety) The ‘second-generation’ or atypical antipsychotics, such asclozapine 3, depicted inFIG. 1 , combine D2 receptor antagonism with activity at other receptors, on the premise that a suitable balance of pharmacological activity should broaden the spectrum of therapeutic efficacy and reduce EPS. With respect to classical neuroleptics, clozapine shows significantly greater efficacy, including an improved effect on negative symptoms, and causes a marked increase in dopamine output in the prefrontal cortex (H. Y. Meltzer, Psychopharmacology, 99, S18 (1989)—incorporated herein by reference in its entirety) Clozapine, however, is associated with its own set of serious side effects including weight gain, diabetes and an increased risk of seizures and agranulocytosis (L. H. Lindstrom, Acta. Psychiatr. Scand., 77, 524 (1988)—incorporated herein by reference in its entirety) - Several preclinical observations suggest that combining 5-HT1A and D2 receptor properties may provide a mutually complementary balance of pharmacological activity with reduced undesirable responses (E. P. Prinssen, F. C. Colpaert, W. Koek, Eur. J. Pharmacol., 453, 217 (2002)—incorporated herein by reference in its entirety) Indeed, numerous mechanistic considerations (A. Newman-Tancredi, M. B. Assie, N. Leduc, A. M. Ormiere, N. Danty, C. Cosi, Int. J. Neuropsychopharmacol., 8, 341 (2005); M. B. Assie, V. Ravailhe, V. Faucillon, A. Newman-Tancredi, J. Pharmacol. Exp. Ther., 315, 265 (2005); L. A. B. Slot, L. D. Vries, A. Newman-Tancredi, D. Cussac, Eur. J. Pharmacol., 534, 63 (2006)—each incorporated herein by reference in its entirety) and preclinical evidence (L. A. B. Slot, M. S. Kleven, Neuropharmacology, 49, 996 (2005); M. S. Kleven, C. Barret-Grevoz, L. A. B. Slot, A. Newman-Tancredi, Neuropharmacology, 49, 135 (2005); R. A. Bantick, J. F. W. Deakin, P. M. Grasby, J. Psychopharmacol., 15, 37 (2001)—each incorporated herein by reference in its entirety) support the potential of such a combination. As a restult, adoprazine 4 (SLV-313) and bifeprunox 5, bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties, were developed as depicted in
FIG. 1 (A. C. McCreary, J. C. Glennon, C. R. Ashby Jr, H. Y. Meltzer, Z. Li, J-H. Reinders, M. B. Hesselink, S. K. Long, A. H. Herremans, H. van Stuivenberg, R. W. Feenstra, C. G. Kruse, Neuropsychopharmacology, 32, 78 (2007)—incorporated herein by reference in its entirety) - The failure of 4 and 5 to oppose phencyclidine-induced social interaction deficits demonstrates the difficulty of balancing activity at these sites (A. Newman-Tancredi, Curr. Opin. Invest. Drugs, 11, 802 (2010)—incorporated herein by reference in its entirety) Compounds having effective ratios of D2 and 5-HT1A activities are described herein (S. Cuisiat, N. Bourdiol, V. Lacharme, A. Newman-Tancredi, F. Colpaert, B. Vacher, J. Med. Chem., 50, 865 (2007)—incorporated herein by reference in its entirety)
- The foregoing paragraphs have been provided by way of general introduction, and are not intended to limit the scope of the following claims. The described embodiments, together with further advantages, will be best understood by reference to the following detailed description taken in conjunction with the accompanying drawings.
- One embodiment of the present invention includes a series of intermediate compounds having the basic bicyclic structure of a dihydroquinazolin compound.
- In another embodiment, the series of intermediate compounds demonstrate D2 receptor antagonist and 5-HT1A receptor agonist properties.
- In another embodiment, the series of intermediate compounds have the piperazinyl moiety attached at the 6-position of the bicyclic dihydroquinazolin ring.
- In another embodiment, 6-(4-(biphenyl-4-ylmethyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- In another embodiment, 6-(4-((4′-fluorobiphenyl-4-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- In another embodiment, 6-(4-((5-phenylpyridin-3-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- In another embodiment, 6-(4-((5-(4-fluorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- In another embodiment, 6-(4-(3-cyclopentenylbenzyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- In another embodiment, 6-(4-((5-cyclopentenylpyridin-3-yl)methyl)piperazin-1-yl)-3,4-dihydroquinazolin-2(1H)-one is an intermediate compound.
- In another embodiment, a method of making the series of intermediate compounds includes using Buchwald-Hartwig coupling a halogenized dihydroquinazolin-2(1H)-one with a tert-butyl piperazine-1-carboxylate.
- A more complete appreciation of the disclosure and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:
-
FIG. 1 displays compounds that bear 5-HT1A receptor agonist and D2 receptor antagonist properties; and -
FIG. 2 displays a series of intermediate compounds. - Referring now to the drawings, wherein like reference numerals designate identical or corresponding parts throughout the several views.
- In an ongoing effort to develop new antipsychotics (N. Ullah, Z. Naturforsch., 67b, 75 (2012); N. Ullah, A. A. Q. Al-Shaheri, Z. Naturforsch., 67b, 253 (2012); N. Ullah, J. Enz. Inhib. Med. Chem., doi:10.3109/14756366.2013.776556 (in press)—each incorporated herein by reference in its entirety), we have synthesized a series of 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones (
FIG. 2 displays compounds 6a-f).FIG. 2 displays the compounds. - In another embodiment, the compounds are used to treat schizophrenia by administering an effective amount of the compound to a patient suffering from schizophrenia. An effective amount of the compound includes but is not limited to using an amount of the compound in which the compound bears D2 receptor antagonist properties and 5-HT1A receptor agonist properties sufficient enough to treat and/or alleviate symptoms of schizophrenia. Symptoms of schizophrenia include but are not limited to auditory hallucinations, visual hallucinations, olfactory hallucinations, gustatory hallucinations, hearing voices, delusions (often bizarre or persecutory in nature), disorganized thinking and speech, social withdrawal, sloppiness of dress and hygiene, loss of motivation and judgment, an observable pattern of emotional difficulty including lack of responsiveness, impairment in social cognition, paranoia, social isolation, difficulties in working and long-term memory, attention, executive functioning, remaining motionless in bizarre postures, exhibiting purposeless agitation, difficulty with facial emotion perception, manifestations of psychosis, expressing little emotion, inability to experience pleasure, and lack of desire to form relationships.
- In another embodiment, the compound can be administered in an amount in the range of 1 mg-5000 mg, 5 mg-100 mg, 5 mg-20 mg, and 5-10 mg. Preferably, the compound is administered in a dose of 5-10 mg. The compound may be administered once a day or twice a day. Preferably the compound is administered once a day at the same time each day. The compound may be administered at any time period of the day.
- In one embodiment of the invention, compositions containing one or more of the compounds can be delivered to a patient by systemic administration. Systemic administration is an in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes that can lead to systemic absorption include but are not limited to intravenous, subcutaneous, intraperitoneal, inhalation, transdermal, oral, intrapulmonary and intramuscular routes.
- In another embodiment, the compositions of the invention and formulations thereof can be administered orally, topically, parenterally, sublingually, by inhalation or spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intradermal, intramuscular, or intrathecal injection or infusion techniques and the like.
- The pharmaceutical compositions can be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring agents or preservative agents in order to provide pharmaceutically acceptable and palatable preparations. Tablets may contain the active ingredient or ingredients in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
- In another embodiment, formulations for oral use can also be presented as hard gelatin capsules wherein the intermediate is mixed with an inert solid diluent including but not limited to calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the intermediate is mixed with water or an oil medium including but not limited to peanut oil, liquid paraffin or olive oil.
- In another embodiment, aqueous suspensions contain the active materials in a mixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin. Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be preserved by the addition of an anti-oxidant such as ascorbic acid.
- In another embodiment, dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.
- In another embodiment, pharmaceutical compositions of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening and flavoring agents.
- In another embodiment, syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutically acceptable compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
- In another embodiment, the compositions can also be administered in the form of suppositories, e.g., for rectal administration of the drugs. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include but are not limited to cocoa butter and polyethylene glycols.Examples:
- General procedure: Melting Points were determined on a Büchi apparatus and are uncorrected. Elemental analysis was carried out on a Perkin Elmer Elemental Analyzer Series 11 Model 2400. IR spectra were recorded on a Perkin Elmer 16F PC FTIR spectrophotometer. 1H and 13C NMR spectra were measured in CDCl3 and d6-DMSO using TMS as internal standard on a JEOL LA 500 MHz spectrometer. Mass spectra were recorded on a GC-MS system (Agilent Technologies, 6890 N). Analytical TLC was carried out on silica gel 60 F254 plates; column chromatography was carried out on Merck silica gel (200-400 mesh).
- In a three neck round bottom flask solution of aldehyde 12 (3 g, 13.0 mmol) in THF (25 mL) was prepared at room temperature. To the solution were added ammonium hydroxide (28%, 5 mL) and sodium borohydride (1.47 g, 39 mmol) simultaneously in portions in such a rate that addition of both was completed in 20 minutes. The mixture was aged at room temperature for 4 h; ethyl acetate (30 mL) and brine (15 mL) were added. The organic layer was separated and washed with brine (15 mL), dried over Na2SO4 and evaporated to get an off-white solid, which was recrystallized from a mixture of ethanol and hexanes (3:7) to afford the title compound 13 as an off-white solid (2.68 g, 89%). IR (KBr) νmax. cm1: 3431, 3319 (NH2), 3052 (Ar—H), 2925 (Alph-H), 1606, 1554 (C═C), 1521, 1432 (NO2), 1230 (C—N), 1188 (C—O). 1H NMR (500 MHz, CDCl3) δ=2.41 (br. s, 2H, NH2), 5.02 (s, 2H, CH2), 7.60 (dd, 1H, J=2.2, 8.2 Hz, H-4), 7.99 (m, 2H, aromatic H). 13C NMR (125.7 MHz, CDCl3) δ=61.95 (CH2), 126.51 (C-3), 129.53 (C-1), 131.45 (C-6), 132.50 (C-4), 139.00 (C-5), 145.99 (C-2). Calculated (%) for C7H7BrN2O2 (229.97); C: 36.39, H: 3.05, N: 12.12, found (%); C: 36.33, H: 3.10, N: 12.02.
- To a solution of compound 13 (2.5 g, 10.82 mmol) in pyridine (20 mL) was added acetic anhydride (2 mL, 21.60 mmol) and the mixture was stirred at room temperature for 12 h. The reaction was added ethyl acetate (30 mL) and the organic layer was washed sequentially with H2O (20 mL), 1N HCl (15 mL×3), brine (15 mL) and dried over Na2SO4 and evaporated to get the title compound as an off-white solid (2.89 g, 98%). IR (KBr) νmax. cm−1: 3419 (NH), 3062 (Ar—H), 2925 (Alph-H), 1695 (C═O), 1604, 1564 (C═C), 1520, 1435 (NO2), 1232 (C—N), 1168 (C—O). 1H NMR (500 MHz, CDCl3) δ=2.19 (s, 3H, CH3); 5.50 (s, 2H, CH2); 7.63 (dd, 1H, J=2.3, 8.6 Hz, H-4); 7.75 (d, 1H, J=2.3, H-6), 8.00 (d, 1H, J=8.6 Hz, H-3). 13C NMR (125.7 MHz, CDCl3) δ=20.78 (CH3), 62.27 (CH2), 126.58 (C-3), 129.03 (C-1), 131.73 (C-6), 131.82 (C-4), 134.34 (C-5), 145.33 (C-2), 170.10 (CO). Calculated (%) for C9H9BrN2O3 (271.98); C: 39.58, H: 3.32, N: 10.26, found (%); C: 39.52, H: 3.36, N: 10.20.
- To an oven-dried flask, 1-boc-piperazine (3.19 g, 17.1 mmol), Cs2CO3 (5.82 g, 17.86 mmol), Pd2(dba)3 (1.44 g, 1.57 mmol), rac-2,2′bis(diphenylphosphino)-1,1′-binaphthyl (0.89 g, 1.43 mmol), toluene (8 mL) and compound 14 (3.89 g, 14.26 mmol) were added. While stirring the reaction mixture at room temperature, the air in the flask was removed and replaced by N2. This process was repeated three times. The reaction temperature was brought to 110° C. and stirred for 8 h. Ethyl acetate (40 mL) was added to the mixture at room temperature, washed with H2O (15 mL), brine (10 mL), dried over Na2SO4 and evaporated. The brown oily material was chromatographed on a silica column, eluting with hexanes:ethyl acetate (3:7) and then changing to (1:1) to obtain the title compound 15 as light yellow solid (3.88 g, 72%). IR (KBr) νmax. cm−1: 3441 (NH), 3060 (Ar—H), 2963 (Alph-H), 1696 (C═O), 1607, 1577 (C═C), 1484, 1421 (NO2), 1243 (C—N), 1168 (C—O). 1H NMR (500 MHz, CDCl3) δ=1.49 (s, 9H, (C(CH3)3), 2.17 (s, 3H, CH3), 3.42 (br. s, 4H, 2CH2), 3.61 (br. s, 4H, 2CH2), 5.54 (s, 2H, CH2), 6.76 (dd, 1H, J=2.3, 9.3 Hz, H-6), 6.88 (br. s, 1H, H-2), 8.17 (d, 1H, J=9.4 Hz, H-5). 13C NMR (125.7 MHz, CDCl3) δ=20.93 (CH3), 28.39 (C(CH3)3), 46.82 (CH2), 50.02 (CH2), 66.12 (CH2), 80.42 (C(CH3)3), 112.30 (aromatic-C), 112.48 (aromatic-C), 128.17 (aromatic-C), 135.60 (aromatic-C), 137.03 (aromatic-C), 153.02 (aromatic-C), 154.56 (CO), 170.29 (CO). Calculated (%) for C18H26N4O5 (378.19); C: 57.13, H: 6.93, N: 14.81, found (%); C: 57.07, H: 6.99, N: 14.71.
- To a solution of compound 15 (1.13 g, 3 mmol) in EtOH (30 mL) was added Ra—Ni (0.20 g, 10% wet basis) and the mixture was subjected to hydrogenation in Parr apparatus at 20 psi for 6 hours. After filtering over the pad of celite, the solution was concentrated and purified over silica column, eluting with CH2Cl2:MeOH (95:5) and then changing to (92:8) afforded compound 16 as a light yellow thick oil (0.85 g, 82%). IR (KBr) νmax. cm−1: 3441, 3421 (NH), 3042 (Ar—H), 2960 (Alph-H), 1699, 1696 (C═O), 1607, 1577 (C═C), 1240 (C—N), 1165 (C—O). 1H NMR (500 MHz, CDCl3) δ=1.48 (s, 9H, (C(CH3)3), 2.16 (s, 3H, CH3), 3.38 (br. s, 4H, 2CH2), 3.52 (br. s, 4H, 2CH2), 5.28 (br. s, 2H, NH2), 5.49 (s, 2H, CH2), 6.78 (dd, 1H, J=2.3, 9.3 Hz, H-6), 6.80 (br. s, 1H, H-2), 6.87 (d, 1H, J=9.2 Hz, H-5). 13C NMR (125.7 MHz, CDCl3) δ=20.97 (CH3), 28.35 (C(CH3)3), 42.53 (CH2), 46.26 (CH2), 62.54 (CH2), 79.85 (C(CH3)3), 112.10 (aromatic-C), 112.38 (aromatic-C), 117.09 (aromatic-C), 130.22 (aromatic-C), 135.03 (aromatic-C), 143.02 (aromatic-C), 154.58 (CO), 170.51 (CO). Calculated (%) for C18H28N4O3 (348.22); C: 62.05, H: 8.10, N: 16.08, found (%); C: 62.00, H: 8.15, N: 16.00.
- To a solution of compound 16 (0.70 g, 2 mmol) in ethanol (20 mL) was added 4M solution of KOH in H2O (4 mL, 16 mmol) and the mixture was stirred at 90 ° C. for 12 h. The mixture was concentrated under reduced pressure to get a brown oil material, which was resolved over silica column eluting with CH2Cl2:MeOH (95:5) and then changing to (90:10) to get compound 17 as light brown thick oil (0.51 g, 84%). IR (KBr) νmax. cm−1: 3421, 3411 (NH), 3053 (Ar—H), 2936 (Alph-H), 1697 (C═O), 1606, 1578 (C═C), 1244 (C—N), 1166 (C—O). 1H NMR (500 MHz, CDCl3) δ=1.47 (s, 9H, (C(CH3)3), 3.10 (br. s, 4H, 2CH2), 3.22 (br. s, 4H, 2CH2), 4.08 (s, 2H, CH2), 4.58 (br. s, 2H, NH2), 5.18 (br. s, 2H, NH2), 6.68 (dd, 1H, J=2.3, 9.3 Hz, H-6), 6.73 (br. s, 1H, H-2), 6.81 (d, 1H, J=9.2 Hz, H-5). 13C NMR (125.7 MHz, CDCl3) δ=28.05 (C(CH3)3), 42.43 (CH2), 45.26 (CH2), 50.54 (CH2), 79.75 (C(CH3)3), 112.01 (aromatic-C), 112.08 (aromatic-C), 117.00 (aromatic-C), 130.28 (aromatic-C), 134.08 (aromatic-C), 143.08 (aromatic-C), 154.70 (CO). Calculated (%) for C16H26N4O2 (306.21); C: 62.72, H: 8.55, N: 18.29, found (%); C: 62.66, H: 8.62, N: 18.20.
- To a solution of compound 17 (1.38 g, 4.5 mmol) in THF (20 mL) at room temperature was CDI (0.80 g, 4.95 mmol) and the reaction was stirred at 80° C. for 6 hr. The mixture was cooled to room temperature and the solid formed was filtered, washed with diethyl ether to afford 0.99 g (72%) of compound 10 as an off-white foam. IR (KBr) νmax. cm−1: 3210, 3162 (NH), 3032 (Ar—H), 1691 (C═O), 1607, 1515, 1419 (C═C). 1H NMR (500 MHz, CDCl3) δ=1.47 (s, 9H, (CH3)3C); 3.06 (m, 4H, 2CH2); 3.52 (m, 4H, 2CH2); 4.49 (s, 2H, CH2); 6.69 (m, 2H, aromatic-H), 6.74 (m, 1H, aromatic-H); 7.82 (br. s, 1H, NH); 13C NMR (125.7 MHz, CDCl3) δ=28.60 (CH3)3C), 43.35 (CH2), 43.90 (CH2), 50.66 (CH2), 80.10 (CH3)3C), 112.11 (aromatic-C), 112.28 (aromatic-C), 117.19 (aromatic-C), 130.18 (aromatic-C), 134.88 (aromatic-C), 143.18 (aromatic-C), 154.62 (CO), 155.93 (C═O). Calculated (%) for C17H24N4O3 (332.18); C: 61.43, H: 7.28, N: 16.86, found (%) C: 61.38, H: 7.32, N: 16.81.
- To a solution of compound 10 (0.7 g, 2.11 mmol) in a mixture of CH2Cl2 (15 mL) and THF (5 mL) at 0° C. was added TFA (5 mL) and the mixture was stirred at room temperature for 6 h. The solvent was evaporated under vacuum to afford 0.66 g (96%) of
compound 6 as a dark brown gum. 1H NMR (500 MHz, DMSO-d6) δ=3.17 (m, 4H, 2CH2), 3.40 (m, 4H, 2CH2), 4.28 (s, 2H, CH2), 6.70 (m, 2H, aromatic-H), 6.73 (m, 1H, aromatic-H), 8.81 (br. s, 1H, NH), 8.86 (br. s, 1H, NH). 13C NMR (125.7 MHz, DMSO-d6) δ=46.11 (CH2), 46.70 (CH2), 48.68 (CH2), 112.21 (aromatic-C), 112.27 (aromatic-C), 117.31 (aromatic-C), 130.28 (aromatic-C), 134.99 (aromatic-C), 143.38 (aromatic-C), 154.82 (C═O). Calculated (%) for C14H16F3N4O2 (329.12); C: 51.06, H: 4.90, N: 17.01, found (%); C: 51.01, H: 4.95, N: 16.95. - To a solution of compound 6 (0.15 g, 0.43 mmol) and biphenyl-4-carbaldehyde a (0.1 g, 0.55 mmol) in DMSO (2 mL) at 0° C. was added Et3N (0.13 mL, 0.97 mmol). After being stirred for 0.5 h at room temperature, NaBH(OAc)3 (0.11 g, 0.53 mmol) was added and the mixture was stirred for 6 h. The reaction was added sat. NaHCO3 solution (5 mL) and stirred for 15 min, followed by the addition of ethyl acetate (20 mL). The organic layer was separated and washed with sat. NaHCO3, brine, and dried over Na2SO4 and evaporated. Column chromatography on silica gel, eluting with methanol:dichloromethane (5:95) and then changing (10:90) afforded 0.102 g (60%) of
compound 6a as an off-white solid. IR (KBr) νmax. cm−1: 3436 (NH), 3052 (Ar—H), 2953 (Alph-H), 1702 (C═O), 1614, 1515, 1425 (C═C), 1229 (C—N), 1162 (C═O). 1H NMR (500 MHz, DMSO-d6) δ=2.76 (m, 4H, 2CH2), 3.18 (m, 4H, 2CH2), 3.67 (s, 2H, CH2), 4.49 (s, 2H, CH2), 6.60 (d, 1H, J=2.3 Hz, aromatic H), 6.70 (dd, 1H, J=2.2, 8.5 Hz, aromatic H), 7.43-7.48 (m, 6H, aromatic H), 7.58-7.62 (m, 4H, aromatic H). 13C NMR (125.7 MHz, DMSO-d6) δ=43.70 (CH2), 48.23 (CH2), 53.03 (CH2), 62.64 (CH2), 114.56 (aromatic-C), 117.64 (aromatic-C), 119.82 (aromatic-C), 124.58 (aromatic-C), 127.19 (aromatic-C), 127.26 (aromatic-C), 127.55 (aromatic-C), 127.90 (aromatic-C), 128.95 (aromatic-C), 129.26 (aromatic-C), 130.25 (aromatic-C), 130.59 (aromatic-C), 136.66 (aromatic-C), 138.22 (aromatic-C), 138.66 (aromatic-C), 140.95 (aromatic-C), 146.88 (aromatic-C), 156.32 (C═O). Calculated (%) for C25H26N4O (398.21); C: 75.35, H: 6.58, N: 14.06, found (%); C: 75.27, H: 6.65, N: 13.96. - Following the same procedure adopted for the synthesis of 6a, the reductive amination of
compound 6 with aldehyde b afforded 0.101 g (55%) of compound 6b as an off-white solid. IR (KBr) νmax. cm−1: 3421 (NH), 3048 (Ar—H), 2953 (Alph-H), 1702 (C═O), 1615, 1515, 1420 (C═C), 1228 (C—N), 1161 (C—O). 1H NMR (500 MHz, DMSO-d6) δ=2.71 (m, 4H, 2CH2), 3.17 (m, 4H, 2CH2), 3.65 (s, 2H, CH2), 4.43 (s, 2H, CH2), 6.66 (d, 1H, J=2.3 Hz, aromatic H), 6.73 (dd, 1H, J=2.2, 8.5 Hz, aromatic H), 7.13-7.15 (m, 3H, aromatic H), 7.40-7.45 (m, 2H, aromatic H), 7.44-7.56 (m, 4H, aromatic H). 13C NMR (125.7 MHz, DMSO-d6) δ=43.76 (CH2), 48.28 (CH2), 53.08 (CH2), 62.66 (CH2), 114.66 (aromatic-C), 115.29 (aromatic-C), 116.18 (aromatic-C), 117.69 (aromatic-C), 119.88 (aromatic-C), 124.65 (aromatic-C), 127.52 (aromatic-C), 129.39 (aromatic-C), 129.46 (aromatic-C), 130.85 (aromatic-C), 131.15 (aromatic-C), 136.69 (aromatic-C), 136.79 (aromatic-C), 138.79 (aromatic-C), 140.89 (aromatic-C), 146.89 (aromatic-C), 156.38 (C═O), 161.64 (aromatic-C). Calculated (%) for C25H25FN4O (416.20); C: 72.09, H: 6.05, N: 13.45, found (%); C: 72.00, H: 6.11, N: 13.37. - Following the same procedure adopted for the synthesis of 6a, the reductive amination of
compound 6 with aldehyde c afforded 0.082 g (48%) of compound 6c as light yellow gum. IR (KBr) νmax. cm−1: 3436, 3192 (NH), 3042 (Ar—H), 2932 (Alph-H), 1690 (C═O), 1622, 1518, 1440 (C═C), 1175 (C—O). 1H NMR (500 MHz, CDCl3) δ=2.72 (m, 4H, 2CH2), 3.12 (m, 4H, 2CH2), 3.62 (s, 2H, CH2), 4.45 (s, 2H, CH2), 6.64-6.72 (m, 3H, aromatic H), 7.10-7.13 (m, 2H, aromatic H), 7.40-7.42 (m, 2H, aromatic H), 7.44-7.48 (m, 3H, aromatic H), 7.62 (m, 2H, aromatic H), 7.91 (s, 1H, aromatic H), 8.55 (s, 1H, aromatic H), 8.92 (s, 1H, aromatic H). 13C NMR (125.7 MHz, CDCl3) δ=43.67 (CH2), 48.13 (CH2), 52.92 (CH2), 62.40 (CH2), 114.46 (aromatic-C), 117.54 (aromatic-C), 119.70 (aromatic-C), 124.38 (aromatic-C), 126.94 (aromatic-C), 127.86 (aromatic-C), 128.38 (aromatic-C), 128.70 (aromatic-C), 128.78 (aromatic-C), 128.89 (aromatic-C), 132.98 (aromatic-C), 133.16 (aromatic-C), 136.18 (aromatic-C), 136.49 (aromatic-C), 136.60 (aromatic-C), 137.36 (aromatic-C), 146.10 (aromatic-C), 146.87 (aromatic-C), 148.86 (aromatic-C), 155.41 (C═O). Calculated (%) for C24H25N5O (399.21); C: 72.16, H: 6.31, N: 17.53, found (%); C: 72.07, H: 6.37, N: 17.41. - Following the same procedure adopted for the synthesis of 6a, the reductive amination of
compound 6 with aldehyde d afforded 0.083 g (49%) of compound 6d as a light yellow solid. IR (KBr) νmax. cm−1: 3426, 3175 (NH), 3040 (Ar—H), 2962 (Alph-H), 1688 (C═O), 1622, 1525, 1420 (C═C), 1172 (C—O). 1H NMR (500 MHz, CDCl3) δ=2.79 (m, 4H, 2CH2), 3.19 (m, 4H, 2CH2), 3.66 (s, 2H, CH2), 4.48 (s, 2H, CH2), 6.62-6.69 (m, 2H, aromatic H), 6.70-6.72 (m, 2H, aromatic H), 7.17 (m, 1H, aromatic H), 7.56-7.58 (m, 2H, aromatic H), 7.89 (s, 1H, aromatic H), 8.54 (s, 1H, aromatic H), 8.70 (s, 1H, NH), 8.96 (s, 1H, aromatic H). 13C NMR (125.7 MHz, CDCl3) δ=43.60 (CH2), 48.19 (CH2), 52.90 (CH2), 61.41 (CH2), 114.32 (aromatic-C), 114.48 (aromatic-C), 115.85 (aromatic-C), 116.76 (aromatic-C), 117.54 (aromatic-C), 119.70 (aromatic-C), 124.38 (aromatic-C), 128.61 (aromatic-C), 129.75 (aromatic-C), 135.28 (aromatic-C), 136.63 (aromatic-C), 146.89 (aromatic-C), 146.96 (aromatic-C), 148.83 (aromatic-C), 150.49 (aromatic-C), 152.80 ((aromatic-C)), 155.06 (C=0), 161.73 (aromatic-C), 163.68 (aromatic-C). Calculated (%) for C24H24FN5O (417.20); C: 69.05, H: 5.79, N: 16.78, found (%); C: 68.96, H: 5.86, N: 16.71. - Following the same procedure adopted for the synthesis of 6a, the reductive amination of
compound 6 with aldehyde e afforded 0.111 g (60%) of compound 6e as light brown foam. IR (KBr) νmax. cm−1: 3416, 3182 (NH), 3045 (Ar—H), 2933 (Alph-H), 1690 (C═O), 1622, 1518, 1421 (C═C), 1167 (C—O). 1H NMR (500 MHz, CDCl3) δ=2.00-2.04 (m, 2H, CH2), 2.51 (m, 2H, CH2), 2.60 (m, 2H, 2CH2), 2.73 (m, 4H, 2CH2), 3.12 (m, 4H, 2CH2), 3.60 (s, 2H, CH2), 4.46 (s, 2H, CH2), 6.19 (s, 1H, CH), 6.58-6.75 (m, 3H, aromatic H), 7.18 (m, 1H, aromatic H), 7.24 (m, 1H, aromatic H), 7.31 (m, 1H, aromatic H), 7.40 (s, 1H, aromatic H), 7.95 (br. s, 1H, NH). 13C NMR (125.7 MHz, CDCl3) δ=23.52 (CH2), 33.46 (CH2), 33.58 (CH2), 43.62 (CH2), 48.18 (CH2), 52.90 (CH2), 62.48 (CH2), 114.48 (aromatic-C), 115.12 (aromatic-C), 117.58 (aromatic-C), 119.72 (aromatic-C), 123.52 (aromatic-C), 124.42 (aromatic-C), 126.59 (aromatic-C), 128.06 (aromatic-C), 128.45 (aromatic-C), 130.07 (aromatic-C), 136.60 (aromatic-C), 137.79 (aromatic-C), 142.58 (aromatic-C), 146.92 (aromatic-C), 156.19 (C═O). Calculated (%) for C24H28N4O (388.23); C: 74.20, H: 7.26, N: 14.42, found (%); C: 74.13, H: 7.33, N: 14.33. - Following the same procedure adopted for the synthesis of 6a, the reductive amination of
compound 6 with aldehyde f afforded 0.090 g (54%) of compound 6f as an off-white solid. IR (KBr) νmax. cm−1: 3412, 3190 (NH), 3061 (Ar—H), 2961 (Alph-H), 1690 (C═O), 1626, 1523, 1422 (C═C), 1170 (C—O). 1H NMR (500 MHz, CDCl3) δ=2.00-2.06 (m, 2H, CH2), 2.50 (m, 2H, CH2), 2.61 (m, 2H, 2CH2), 2.71 (m, 4H, 2CH2), 3.15 (m, 4H, 2CH2), 3.61 (s, 2H, CH2), 4.45 (s, 2H, CH2), 6.20 (s, 1H, CH), 6.58-6.75 (m, 3H, aromatic H), 6.78 (m, 1H, aromatic H), 7.71 (s, 1H, NH), 8.09 (s, 1H, aromatic H), 8.42 (s, 1H, aromatic H), 8.58 (s, 1H, aromatic H). 13C NMR (125.7 MHz, CDCl3) δ=23.92 (CH2), 33.56 (CH2), 33.88 (CH2), 43.69 (CH2), 48.12 (CH2), 52.92 (CH2), 62.68 (CH2), 114.43 (aromatic-C), 115.92 (aromatic-C), 117.44 (aromatic-C), 119.76 (aromatic-C), 124.39 (aromatic-C), 130.92 (aromatic-C), 133.09 (aromatic-C), 133.69 (aromatic-C), 136.60 (aromatic-C), 140.37 (aromatic-C), 146.90 (aromatic-C), 147.91 (aromatic-C), 149.46 (aromatic-C), 156.90 (C=0). Calculated (%) for C23H27N5O (389.22); C: 70.92, H: 6.99, N: 17.98, found (%); C: 70.86, H: 7.06, N: 17.91. - To accomplish the synthesis of the desired
compounds 6a-f, synthesis of the key intermediate (10) was required, which in turn was envision from the Buchwald-Hartwig coupling reaction of 6-bromo-3,4-dihydroquinazolin-2(1H)-one (9) (H. Venkatesan, F. M. Hocutt, T. K. Jones, M. H. Rabinowitz, J. Org. Chem., 75, 3488 (2010)—incorporated herein by reference in its entirety) with tert-butyl piperazine-1-carboxylate. Thus the synthesis of compound (9) was commenced with the reduction of bromobenzonitrile with borane to afford diamine (8), which was reacted with triphosgene to get the desired bromide (9) in 23% overall yield from (7). However, the Buchwald-Hartwig coupling of bromides 9 with tert-butyl piperazine-1-carboxylate, under different reaction conditions (PdCl2dppf, KOAc, DMF, 80° C.; Pd(PPh3)4, toluene, ethanol, Na2CO3, reflux) were not successful; the desired 10 was not observed in any case (scheme 1). - Therefore an alternative approach was adopted in which benzaldehyde 11 was nitrated to the known benzaldehyde 12, which in turn was subjected to reductive amination by condensing it with ammonium hydroxide, using sodium borohydride as reducing agent to produce amine 13 in high yield. Acetylation amine 13 generated acetamide 14, which was reacted with tert-butyl piperazine-1-carboxylate under Buchwald-Hartwig conditions to afford intermediate 15 in good yield. Reduction of nitro group of 15 over Pd—C in a Parr apparatus produced intermediate 16 in 91% yield high yield. Exposure of intermediate 16 under basic conditions rendered the desired diamine 17 in good yield after column purifications. Reaction of 17 with CDI in THF, heating the mixture at 80° C. for 6 hours, gave access to the key intermediate 10 in an overall yield of 33% from 14. Exposure of intermediate 10 to trifluoroacetic acid in a mixture of methanol and dichloromethane finally furnished the desired key intermediate 18 (scheme 2).
- Having the desired intermediates 18 in hands, reductive amination of 18 with aldehydes (a-f)15 in DMSO was performed, using NaBH(OAc)3 as reducing agent to accomplish the synthesis of final compounds (6a-f) (scheme 3).
- A series of new 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties have been synthesized.
- Thus, the foregoing discussion discloses and describes merely exemplary embodiments of the present invention. As will be understood by those skilled in the art, the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. Accordingly, the disclosure of the present invention is intended to be illustrative, but not limiting of the scope of the invention, as well as other claims. The disclosure, including any readily discernible variants of the teachings herein, define, in part, the scope of the foregoing claim terminology such that no inventive subject matter is dedicated to the public.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/848,058 US9205087B1 (en) | 2014-02-19 | 2015-09-08 | 6-Piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/184,339 US9145388B2 (en) | 2014-02-19 | 2014-02-19 | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
US14/848,058 US9205087B1 (en) | 2014-02-19 | 2015-09-08 | 6-Piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/184,339 Continuation US9145388B2 (en) | 2014-02-19 | 2014-02-19 | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
Publications (2)
Publication Number | Publication Date |
---|---|
US9205087B1 US9205087B1 (en) | 2015-12-08 |
US20150374695A1 true US20150374695A1 (en) | 2015-12-31 |
Family
ID=53797501
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/184,339 Expired - Fee Related US9145388B2 (en) | 2014-02-19 | 2014-02-19 | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
US14/848,058 Expired - Fee Related US9205087B1 (en) | 2014-02-19 | 2015-09-08 | 6-Piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
US14/848,008 Expired - Fee Related US9199969B1 (en) | 2014-02-19 | 2015-09-08 | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/184,339 Expired - Fee Related US9145388B2 (en) | 2014-02-19 | 2014-02-19 | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/848,008 Expired - Fee Related US9199969B1 (en) | 2014-02-19 | 2015-09-08 | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
Country Status (1)
Country | Link |
---|---|
US (3) | US9145388B2 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002505288A (en) | 1998-03-02 | 2002-02-19 | コセンシス,インコーポレイテッド | Substituted quinazolines and analogs and their uses |
KR20070110081A (en) | 2005-03-09 | 2007-11-15 | 머크 앤드 캄파니 인코포레이티드 | Quinazolinone t-type calcium channel antagonists |
TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
-
2014
- 2014-02-19 US US14/184,339 patent/US9145388B2/en not_active Expired - Fee Related
-
2015
- 2015-09-08 US US14/848,058 patent/US9205087B1/en not_active Expired - Fee Related
- 2015-09-08 US US14/848,008 patent/US9199969B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20150232448A1 (en) | 2015-08-20 |
US9199969B1 (en) | 2015-12-01 |
US9145388B2 (en) | 2015-09-29 |
US9205087B1 (en) | 2015-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5216912B2 (en) | Indazole compounds as CCR1 receptor antagonists | |
US5308854A (en) | Inhibitors of HIV reverse transcriptase | |
CA2402751C (en) | Decahydro-isoquinolines | |
TW200304910A (en) | Acetylene derivatives having MGluR5 antagonistic activity | |
JP2008526715A (en) | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders | |
TW200901992A (en) | Triazolopyridine carboxamide and triazolopyrimidine carboxamide derivatives, their preparation and their application in therapeutics | |
MX2007015678A (en) | Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor. | |
FR2786185A1 (en) | 3-AMINOMETHYLPYRROLIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR PREPARING THEM | |
FR2785902A1 (en) | 4-AROYLPIPERIDINES ANTAGONISTS OF THE CCR-3 RECEPTOR, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD FOR USING AND PREPARING THEM | |
CN108260355A (en) | The conditioning agent of indole amine 2,3-dioxygenase | |
JP2022107730A (en) | 2-SUBSTITUTED AMINO-NAPHTH[1,2-d]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | |
RU2497819C2 (en) | Compositions, synthesis and method for using atypical antipsychotic drugs of quinoline | |
JP6755950B2 (en) | Lactam compound derivatives and their applications | |
US20130150437A1 (en) | Naphthoquinones for disease therapies | |
JPS6191157A (en) | Tetrahydronaphthalene derivative | |
KR20110110759A (en) | Use of indole derivatives as nurr-1 activators for treating parkinson's disease | |
TWI257392B (en) | Isoxazolines derivatives and their use as anti-depressants | |
JP7091437B2 (en) | Oxindole compound and its pharmaceutical composition | |
KR100860692B1 (en) | Cyclic diamine compounds having fused-ring groups | |
JP2005530691A (en) | Novel tyroindicins and related processes, pharmaceutical compositions and methods | |
US9205087B1 (en) | 6-Piperazinyl-3,4-dihydroquinazolin-2(1H)-ones | |
WO2005028455A1 (en) | Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient | |
CN1318053A (en) | Cyclopentanoue dihydropyridine compounds useful as potassium channel openers | |
AU2016240069B2 (en) | Indole analogs as 5-oxo-ETE receptor antagonists and method of use thereof | |
TW200831463A (en) | Nitrate esters of aminoalcohols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20231208 |